NEW USE FOR 1,3-PROPANEDIOL DERIVATIVES

NOUVELLE UTILISATION DE DERIVES DE 1,3-PROPANEDIOL

English Abstract

Use of a compound of formula (I) wherein R1 is an optionally substituted
straight- or branched carbon chain having 12 to 22 carbon atoms which may be
optionally interrupted by an optionally substituted phenylene, and each of R2,
R3,
R4 and R5, independently, is H or lower alkyl, in free form or in
pharmaceutically
acceptable salt form, in the prevention or treatment of chronic rejection in a
recipient
of organ or tissue allo- or xenotransplant, or of acute rejection in a
xenograft transplant
recipient.

French Abstract

Cette invention concerne l'utilisation d'un composé de la formule (I) dans laquelle R1 est une chaîne de carbone droite ou ramifiée éventuellement substituée comprenant 12 à 22 atomes de carbone et pouvant être éventuellement interrompue par un phénylène éventuellement substitué; R2, R3, R4 et R5 sont chacun, indépendamment, H ou alkyle inférieur, sous forme libre ou de sel pharmaceutiquement acceptable. Ledit composé est utile dans la prévention ou le traitement d'un rejet chronique chez un receveur d'organe ou de tissu allogreffé ou xénotransplanté, ou d'une crise de rejet chez un sujet ayant subi une hétérotransplantation.

Claims

-10-
CLAIMS:
1. Use of a compound of formula I
<IMG>
wherein
R1 is an optionally substituted straight- or
branched carbon chain having 12 to 22 carbon atoms which may
be optionally interrupted by an optionally substituted
phenylene, and
each of R2, R3, R4 and R5, independently, is H or
lower alkyl,
in free form or in pharmaceutically acceptable
salt form,
for preventing or treating manifestations of
chronic graft rejection in a recipient of organ or tissue
allotransplant.
2. Use according to claim 1, wherein the compound of
formula I is 2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-
propanediol, in free form or in pharmaceutically acceptable
salt form.
3. Use according to claim 1, wherein the compound is
2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol
hydrochloride.

-11-
4. Use of a compound of formula I
<IMG>
wherein
R1 is an optionally substituted straight- or
branched carbon chain having 12 to 22 carbon atoms which may
be optionally interrupted by an optionally substituted
phenylene, and
each of R2, R3, R4 and R5, independently, is H or
lower alkyl,
in free form or in pharmaceutically acceptable
salt form,
for preventing or treating graft vessel diseases
in a recipient of organ or tissue allotransplant.
5. Use according to claim 4, wherein the compound of
formula I is 2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-
propanediol, in free form or in pharmaceutically acceptable
salt form.
6. Use according to claim 4, wherein the compound is
2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol
hydrochloride.

-12-
7. Use of a compound of formula I
<IMG>
wherein
R1 is an optionally substituted straight- or
branched carbon chain having 12 to 22 carbon atoms which may
be optionally interrupted by an optionally substituted
phenylene, and
each of R2, R3, R4 and R5, independently, is H or
lower alkyl,
in free form or in pharmaceutically acceptable
salt form,
in manufacture of a medicament for preventing or
treating manifestations of chronic graft rejection in a
recipient of organ or tissue allotransplant.
8. Use according to claim 7, wherein the compound of
formula I is 2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-
propanediol, in free form or in pharmaceutically acceptable
salt form.
9. Use according to claim 7, wherein the compound is
2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol
hydrochloride.
10. Use of a compound of formula I
<IMG>

-13-
wherein
R1 is an optionally substituted straight- or
branched carbon chain having 12 to 22 carbon atoms which may
be optionally interrupted by an optionally substituted
phenylene, and
each of R2, R3, R4 and R5, independently, is H or
lower alkyl,
in free form or in pharmaceutically acceptable
salt form,
in manufacture of a medicament for preventing or
treating graft vessel diseases in a recipient of organ or
tissue allotransplant.
11. Use according to claim 10, wherein the compound of
formula I is 2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-
propanediol, in free form or in pharmaceutically acceptable
salt form.
12. Use according to claim 10, wherein the compound is
2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol
hydrochloride.
13. A compound of formula I
<IMG>
wherein
R1 is an optionally substituted straight- or
branched carbon chain having 12 to 22 carbon atoms which may
be optionally interrupted by an optionally substituted
phenylene, and

-14-
each of R2, R3, R4 and R5, independently, is H or
lower alkyl,
in free form or in pharmaceutically acceptable
salt form,
for preventing or treating manifestations of
chronic graft rejection in a recipient of organ or tissue
allotransplant.
14. A compound or salt according to claim 13, wherein
the compound of formula I is 2-amino-2-[2-(4-
octylphenyl)ethyl]-1,3-propanediol, in free form or in
pharmaceutically acceptable salt form.
15. A compound or salt according to claim 13, wherein
the compound is 2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-
propanediol hydrochloride.
16. A compound of formula I
<IMG>
wherein
R1 is an optionally substituted straight- or
branched carbon chain having 12 to 22 carbon atoms which may
be optionally interrupted by an optionally substituted
phenylene, and
each of R2, R3, R4 and R5, independently, is H or
lower alkyl,
in free form or in pharmaceutically acceptable
salt form,

-15-
for preventing or treating graft vessel diseases
in a recipient of organ or tissue allotransplant.
17. A compound or salt according to claim 16, wherein
the compound of formula I is 2-amino-2-[2-(4-
octylphenyl)ethyl]-1,3-propanediol, in free form or in
pharmaceutically acceptable salt form.
18. A compound or salt according to claim 16, wherein
the compound is 2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-
propanediol hydrochloride.
19. A pharmaceutical composition comprising a
pharmaceutically acceptable carrier or diluent and a
compound of formula I
<IMG>
wherein
R1 is an optionally substituted straight- or
branched carbon chain having 12 to 22 carbon atoms which may
be optionally interrupted by an optionally substituted
phenylene, and
each of R2, R3, R4 and R5, independently, is H or
lower alkyl,
in free form or in pharmaceutically acceptable
salt form,
for preventing or treating manifestations of
chronic graft rejection in a recipient of organ or tissue
allotransplant.

-16-
20. A pharmaceutical composition according to
claim 19, wherein the compound of formula I is 2-amino-2-[2-
(4-octylphenyl)ethyl]-1,3-propanediol, in free form or in
pharmaceutically acceptalbe salt form.
21. A pharmaceutical composition according to
claim 19, wherein the compound is 2-amino-2-[2-(4-
octylphenyl)ethyl]-1,3-propanediol hydrochloride.
22. A pharmaceutical composition comprising a
pharmaceutically acceptable carrier or diluent and a
compound of formula I
<IMG>
wherein
R1 is an optionally substituted straight- or
branched carbon chain having 12 to 22 carbon atoms which may
be optionally interrupted by an optionally substituted
phenylene, and
each of R2, R3, R4 and R5, independently, is H or
lower alkyl,
in free form or in pharmaceutically acceptable
salt form,
for preventing or treating graft vessel diseases
in a recipient of organ or tissue allotransplant.
23. A pharmaceutical composition according to
claim 22, wherein the compound of formula I is a 2-amino-2-
[2-(4-octylphenyl)ethyl]-1,3-propanediol, in free form or in
pharmaceutically acceptable salt form.

-17-
24. A pharmaceutical composition according to
claim 22, wherein the compound is 2-amino-2-[2-(4-
octylphenyl)ethyl]-1,3-propanediol hydrochloride.
25. Use according to any one of claims 1 to 6, wherein
the compound or salt is for combination with an
immunosuppressant or immunomodulatory drug.
26. Use according to claim 25, wherein the
immunosuppressant or immunomodulatory drug is selected from
cyclosporin A, FK-506, azathioprine, methotrexate,
mycophenolic acid, mycophenolate mofetil, rapamycin, 40-O-
(2-hydroxyethyl)-rapamycin, 15-deoxyspergualine, monoclonal
antibodies to leukocyte receptors, monoclonal antibodies to
ligands of the leukocyte receptors, and CTLA4-lg.
27. Use according to claim 26, wherein the leukocyte
receptors are selected from CD2, CD3, CD4, CD7, CD25, CD28,
B7, CD40 and CD45 and the ligands of the leukocyte receptors
are selected from ligands of CD2, CD3, CD4, CD7, CD25, CD28,
B7, CD40 and CD45.
28. Use according to any one of claims 7 to 12,
wherein the compound or salt is for combination with an
immunosuppressant or immunomodulatory drug.
29. Use according to claim 28, wherein the
immunosuppressant or immunomodulatory drug is selected from
cyclosporin A, FK-506, azathioprine, methotrexate,
mycophenolic acid, mycophenolate mofetil, rapamycin, 40-O-
(2-hydroxyethyl)-rapamycin, 15-deoxyspergualine, monoclonal
antibodies to leukocyte receptors, monoclonal antibodies to
ligands of the leukocyte receptors, and CTLA4-lg.
30. Use according to claim 29, wherein the leukocyte
receptors are selected from CD2, CD3, CD4, CD7, CD25, CD28,

-18-
B7, CD40 and CD45 and the ligands of the leukocyte receptors
are selected from ligands of CD2, CD3, CD4, CD7, CD25, CD28,
B7, CD40 and CD45.
31. A compound or salt according to any one of
claims 13 to 18, wherein the compound or salt is for
combination with an immunosuppressant or immunomodulatory
drug.
32. A compound or salt according to claim 31, wherein
the immunosuppressant or immunomodulatory drug is selected
from cyclosporin A, FK-506, azathioprine, methotrexate,
mycophenolic acid, mycophenolate mofetil, rapamycin, 40-O-
(2-hydroxyethyl)-rapamycin, 15-deoxyspergualine, monoclonal
antibodies to leukocyte receptors, monoclonal antibodies to
ligands of the leukocyte receptors, and CTLA4-lg.
33. A compound or salt according to claim 32, wherein
the leukocyte receptors are selected from CD2, CD3, CD4,
CD7, CD25, CD28, B7, CD40 and CD45 and the ligands of the
leukocyte receptors are selected from ligands of CD2, CD3,
CD4, CD7, CD25, CD28, B7, CD40 and CD45.
34. A pharmaceutical composition according to any one
of claims 19 to 24, wherein the compound or salt is for
combination with an immunosuppressant or immunomodulatory
drug.
35. A pharmaceutical composition according to
claim 34, wherein the immunosuppressant or immunomodulatory
drug is selected from cyclosporin A, FK-506, azathioprine,
methotrexate, mycophenolic acid, mycophenolate mofetil,
rapamycin, 40-O-(2-hydroxyethyl)-rapamycin, 15-
deoxyspergualine, monoclonal antibodies to leukocyte
receptors, monoclonal antibodies to ligands of the leukocyte
receptors, and CTLA4-lg.

-19-
36. A pharmaceutical composition according to claim
35, wherein the leukocyte receptors are selected from CD2,
CD3, CD4, CD7, CD25, CD28, B7, CD40 and CD45 and the ligands
of the leukocyte receptors are selected from ligands of CD2,
CD3, CD4, CD7, CD25, CD28, B7, CD40 and CD45.

Description

CA 02270952 2006-07-20
21489-9517
-1-
New Use For 1,3-Propanediol Derivatives
The present invention relates to a new use for a compound group comprising
2-amino-1,3-propanediol derivatives.
Compounds for use according to the invention are compounds of formula I
CH2OR3
I
R5R4N-C- CHzQRz
I
CHZ- R1
wherein
R, is an optionally substituted straight- or branched carbon chain
having 12 to 22 carbon atoms which may be optionally interrupted by an
optionally
substituted phenylene, and
each of R2, R3, R4 and R5, independently, is H or lower alkyl,
in free form or in pharmaceutically acceptable salt form. -
When the carbon chain as R, is substituted, it is preferably substituted by
halogen, nitro,
amino, hydroxy or carboxy. When the carbon chain is interrupted by an
optionally
substituted phenylene, the carbon chain is preferably unsubstituted. When the
phenylene
moiety is substituted, it is preferably substituted by halogen, nitro, amino,
methoxy, hydroxy
or carboxy.
Such compounds are disclosed in EP-A1-627,406.
Preferred compounds of formula I are those wherein R, is a straight or
branched, preferably
straight, chain alkyl having 13 to 20 carbon atoms, optionally substituted by
nitro, halogen,

CA 02270952 1999-05-03
WO 98/22100 PCT/EP97/06408
-2-
amino, hydroxy or carboxy, and, more preferably those wherein R, is
phenylalkyl substituted
by a straight or branched C6_14 alkyl chain optionally substituted by halogen
and the alkyl
moiety is a C,_6 alkyl optionally substituted by hydroxy. More preferably, R,
is phenyl-C1.6
alkyl substituted on the phenyl by a straight or branched, preferably
straight, C6_14 alkyl
chain. The C6_14 alkyl chain may be in ortho, meta or para, preferably in
para.
Preferably each of R2 to R5 is H.
Examples of the pharmaceutically acceptable salts of the compounds of the
formula (1)
include salts with inorganic acids, such as hydrochloride, hydrobromide and
sulfate, salts
with organic acids, such as acetate, fumarate, maleate, benzoate, citrate,
malate,
methanesulfonate and benzenesulfonate salts, and when a carboxy group is
present, salts
with metals such as sodium, potassium, calcium and aluminium, salts with
amines, such as
triethylamine and salts with dibasic amino acids, such as lysine. The
compounds and salts
of the present invention encompass hydrate and solvate forms.
When the compounds of formula I have one or more asymmetric centers in the
molecule,
the present invention is to be understood as embracing the various optical
isomers, as well
as racemates, diastereoisomers and mixtures thereof are embraced.
Particularly preferred compounds of formula I are 2-amino-2-tetradecyl-1,3-
propanediol and
especially 2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol, (hereinafter
Compound A)
e.g. in hydrochloride form.
Compounds of formula I have, on the basis of observed activity, e.g. as
described in
EP-A1-627,406 been found to be useful e.g. as immunosuppressant, e.g. in the
treatment
of acute allograft rejection.
Organ transplants of liver, kidney, lung and heart are now regularly performed
as treatment
for endstage organ disease. Allograft as well as xenograft transplants have
been
performed. However, because of problems with long-term chronic rejection,
organ
transplantation is not yet a permanent solution to irreversible organ disease.
Chronic rejection, which manifests as progressive and irreversible graft
dysfunction, is the
leading cause of organ transplant loss, in some cases already after the first
postoperative

CA 02270952 1999-05-03
WO 98/22100 PCT/EP97/06408
-3-
year. The clinical problem of chronic rejection is clear from transplantation
survival times;
about half of kidney allografts are lost within 5 years after transplantation,
and a similar
value is observed in patients with a heart allograft.
Chronic rejection is considered as a multifactorial process in which not only
the immune
reaction towards the graft but also the response of the blood vessel wall in
the grafted
organ to injury ("response-to-injury" reaction) plays a role. The variant of
chronic rejection
with the worst prognosis is an arteriosclerosis-like alteration, also called
transplant
vasculopathy graft vessel disease, graft atherosclerosis, transplant coronary
disease, etc.
This vascular lesion is characterized by migration and proliferation of smooth
muscle cells
under influence of growth factors, that are amongst others synthesized by
endothelium. It
appears to progress also through repetitive endothelial injury induced amongst
others by
host antibody or antigen-antibody complexes, through intimal proliferation and
thickening,
smooth muscle cell hypertrophy repair, and finally to gradual luminal
obliteration. Also
so-called non-immunological factors like hypertension, hyperlipidemia,
hypercholesterolemia
etc. play a role.
Chronic rejection appears to be inexorable and uncontrollable because there is
no known
effective treatment or prevention modality. Thus, there continues to exist a
need for a
treatment effective in preventing, controlling or reversing manifestations of
chronic graft
vessel diseases.
In accordance with the present invention, it has now surprisingly been found
that
compounds of formula I in free form or in pharmaceutically acceptable salt
form inhibit graft
vessel disease and are particularly indicated to prevent or treat chronic
rejection in a
transplanted organ.
Furthermore, it has also been found that compounds of formula I in free form
or in
pharmaceutically acceptable salt form suppress xenograft rejection.
In accordance with the particular findings of the present invention, there is
provided:
1.1. A method of preventing or treating manifestations of chronic rejection,
e.g. to
avoid, reduce or restrict chronic rejection, in a recipient of organ or tissue
allo- or
xeno-transplant, e.g. heart, lung, combined heart-lung, liver, kidney or
pancreatic

CA 02270952 1999-05-03
WO 98/22100 PCT/EP97/06408
-4-
transplant, comprising the step of administering to said recipient a
therapeutically
effective amount of a compound of formula I in free form or in
pharmaceutically
acceptable salt form;
1.2. A method of preventing or treating graft vessel diseases, e.g. transplant
vasculopathy, arteriosclerosis or atherosclerosis, in a recipient of organ or
tissue
allo- or xeno-transplant, e.g. heart, lung, combined heart-lung, liver, kidney
or
pancreatic transplants, comprising the step of administering to said recipient
a
therapeutically effective amount of a compound of formula I in free form or in
pharmaceutically acceptable salt form;
In a series of further specific or alternative embodiments, the present
invention also
provides:
2. A method of preventing or controlling acute rejection in a xenograft
transplant
recipient, e.g. a patient receiving a heart, lung, combined heart-lung,
kidney, liver,
bone marrow, pancreatic bowel, skin or corneal xenotransplant, comprising
administering to said recipient a therapeutically effective amount of a
compound of
formula I in free form or in pharmaceutically acceptable salt form.
As alternative to the above the present invention also provides:
3. A compound of formula I in free form or in pharmaceutically acceptable salt
form for
use in any method as defined under 1 or 2 above; or
4. A compound of formula I in free form or in pharmaceutically acceptable salt
form for
use in the preparation of a pharmaceutical composition for use in any method
as
defined under 1 or 2 above; or
5. A pharmaceutical composition for use in any method as defined under 1 or 2
above
comprising a compound of formula I in free form or in pharmaceutically
acceptable salt
form together with one or more pharmaceutically acceptable diluents or
carriers
therefor.

CA 02270952 2006-07-20
21489-9517
-5-
Utility of the compounds of formula I in free form or in pharmaceutically
acceptable salt form
in chronic rejection, as well as utility in treating diseases and conditions
as hereinabove
specified, may be demonstrated in animal tests for example in accordance with
the methods
hereinafter described, as well as in clinic where e.g. the transplanted organ
or tissue may
be submitted to regular biopsy controls and in the case of heart transplant
additionally to
ultrasound scanning.
A. Prevention of Graft Vessel Disease
Experimental animals:
Inbred rat strains DA (RT1a, donors) and Lewis (RT11, recipients of
allografts), weighing
between 200 and 350 grams are used. The animals are allowed unrestricted
access to
food and water before and after the operation.
Carotid artery transplantation:
The rats are anaesthetised with isofluorane (Abbott), (4-5 % for induction,
1.5-2 % for
maintenance) and 300 pg atropin sulphate is injected subcutaneously following
the
induction. The left carotid artery is dissected free. The artery is clamped
proximally
and distally and a segment of about 7-10 mm is removed. The gap is bridged by
an
TM
allograft which had also been subjected to 45 min cold ischemia. Ethilon 10/o
sutures
TM
are used. Finally the skin is closed with 4/0 sutures. If needed, an Alzet
osmotic
minipump (Alza Corp. Palo Alto, Calif.) is then implanted subcutaneously over
the back
(alternatively the animals are treated orally).
The rats are subject to one of the following treatments: A compound of formula
I alone
at the doses of 0.1 to 10 mg/kg, or in combination with Cyclosporin A at the
dose of
0.03, 0.3, or 1 mg=kg-'=day-' is administered for 8 weeks either by using
Alzet osmotic
minipumps implanted subcutaneously or alternatively by oral administration.
At 8 weeks the rats are sacrificed, the carotid arteries are perfused for 1
min with 0.1 M
phosphate buffered saline solution (PBS, pH 7.4) and then for 15 min with 2.5
%
glutaraldehyde in phosphate buffer (pH 7.4). The carotid arteries are then
excised and
stained in Giemsa solution for histological evaluation.
Morphometric analysis includes the measurement of the thickness of the media
and
intima. A qualitative analysis of the morphological changes includes a scoring
on an

CA 02270952 1999-05-03
WO 98/22100 PCT/EP97/06408
-6-
0-3 scale for adventitial infiltration of mononuclear cells and necrosis
(vacuolar
degeneration, hypertrophy of cells), the number of smooth muscle cells (SMC)
nuclei in
the media (0-10, <100, >100 and 100 nuclei for scores, 0, 1, 2 and 3
respectively,
SMC necrosis (vacuolar degeneration and hypertrophy of SMC) and the intimal
infiltration of mononuclear cells (13).
In both experiments, the compounds of formula l, particularly Compound A in
hydrochloride form, significantly inhibit graft infiltration and neointima
formation.
B. In vivo heart xenotransplantation (hamster-to-rat)
The hamster-into-rat xenograft combination is a so-called difficult concordant
combination. Rats do not have natural anti-hamster antibody in sufficient
amounts to
yield immediate hyperacute rejection as observed in concordant combinations;
however, rejection in untreated recipients occurs within 3-4 days, by
antibodies in
combination with complement. This is visualized in histology by destruction of
blood
vessels, exsudation and extravasation of erythrocytes, and influx by
polymorphonuclear
granulocytes; often there are signs of hemorrhage and thrombosis. Once this
rejection
has been overcome by effective inhibition of antibody synthesis or complement
inactivation, a cellular rejection can emerge later on. This is visualized in
histology by
influx of mononuclear cells, including lymphocytes, lymphoblastoid cells, and
macro-
phages, and destruction of the myocyte parenchyma. The inhibition of cellular
rejection
requires more immuno- suppression than that of allografts. Congenitally
athymic
(rnu/rnu) rats lack a competent (thymus-dependent) cellular immune system and
generally are unable to reject allografts. Such animals do reject a hamster
xenograft
within 3-4 days in a similar fashion as euthymic rats, indicative that (at
least part of)
anti-hamster antibody synthesis in rats occurs following a thymus-independent
B-cell
response. Such recipients are useful in hamster xenografting to evaluate
rejection by
thymus-independent antibody-mediated rejection.
The heart of a Syrian hamster is heterotopically transplanted in the abdomen
of a male
Lewis (RT1') rat with anastomoses between the donor and recipient's aorta and
the
donor right pulmonary artery to the recipient's inferior vena cava. The graft
is
monitored daily by palpation of the abdomen. Rejection is concluded in case of
cessation of heart beat. Animals are weighed weekly. In the present series of

CA 02270952 1999-05-03
WO 98/22100 PCT/EP97/06408
-7-
experiments, the endpoint is set to 28 days. Animals are subjected to autopsy;
apart
from the graft, weight and histology is assessed for thymus, spleen, liver,
seminal
vesicles and testes. Blood is taken and processed to serum for the
determination of
cytolytic anti-hamster erythrocyte antibody and hemolytic complement activity.
Compounds are dissolved in water and administered daily orally in a volume of
2 mI/kg
body weight. Administration of 5-30 mg/kg/day, of a compound of Formula I,
e.g.
Compound A in hydrochloride form, results in prolonged graft survival, in both
athymic
and euthymic recipients.
Daily dosages required in practicing the method of the present invention will
vary depending
upon, for example, the compound of formula I employed, the host, the mode of
administration, the severity of the condition to be treated, and the
optionally concomitantly
used immunosuppressive drug e.g. CysA. A preferred daily dosage range is about
from
0.03 to 2.5 mg/kg per day, particularly 0.1 to 2.5 mg/kg per day, e.g. 0.5 to
2.5 mg/kg per
day as a single dose or in divided doses. Suitable daily dosages for patients
are on the
order of from e.g. 1 to 100 mg p.o. Suitable unit dosage forms for oral
administration
comprise from ca. 1 to 50 mg, usually 5 to 30 mg active ingredient, e.g.
Compound A, e.g.
in hydrochloride form, together with one or more pharmaceutically acceptable
diluents or
carriers therefor. As an alternative, the compound of formula I in free form
or in
pharmaceutically acceptable salt form may also be administered twice or three
times a
week, e.g. at a dosage as indicated above.
The compounds of formula I may be administered by any conventional route, in
particular
enterally, e.g. orally, for example in the form of solutions for drinking,
tablets or capsules or
parenterally, for example in the form of injectable solutions or suspensions.
Pharmaceutical
compositions comprising the compounds of formula I may be manufactured in
conventional
manner, e.g. as described in EP-A1-627,406.
The compounds of formula I may be administered as the sole active ingredient
or together
with other drugs in immunomodulating regimens or other anti-inflammatory
agents. For
example, the compounds of formula I may be used in combination with
cyclosporins,
rapamycins or ascomycins, or their immunosuppressive analogs, e.g. cyclosporin
A,
cyclosporin G, FK-506, rapamycin, 40-0-(2-hydroxy)ethyl-rapamycin, etc.;
corticosteroids;

CA 02270952 1999-05-03
WO 98/22100 PCT/EP97/06408
-8-
cyclophosphamide; azathioprene; methotrexate; brequinar; leflunomide;
mizoribine;
mycophenolic acid; mycophenolate mofetil; 15-deoxyspergualine; immuno-
suppressive
monoclonal antibodies, e.g., monoclonal antibodies to leukocyte receptors,
e.g., to MHC,
CD2, CD3, CD4, CD7, CD25, CD28, B7, CD40, CD45, or CD58 or to their ligands;
or other
immunomodulatory compounds, e.g. CTLA4-Ig.
Where the compounds of formula I are administered in conjunction with other
immunosuppressive / immunomodulatory therapy, e.g. for preventing or treating
chronic
rejection as hereinabove specified, dosages of the co-administered
immunosuppressant or
immuno-modulatory compound will of course vary depending on the type of co-
drug
employed, e.g. whether it is a steroid or a cyclosporin, on the specific drug
employed, on
the condition being treated, and so forth. In accordance with the foregoing
the present
invention provides in a yet further aspect:
6. A method as defined above comprising co-administration, e.g. concomitantly
or in
sequence, of a therapeutically effective amount of a compound of formula I and
a
second drug substance, said second drug substance being an immunosuppressant
or
immunomodulatory drug, e.g. as set forth above.
7. A kit or package for use in any method as defined under 1 or 2 above,
comprising a
compound of formula I, in free form or in pharmaceutically acceptable salt
form, with at
least one pharmaceutical composition comprising an immunosuppressant or
immunomodulatory drug. The kit or package may comprise instructions for its
administration.
Formulation Example: soft capsules
Compound of formula I,
e.g. Compound A 30 mg
Polyethylene glycol 300 300 mg
Polysorbate 80 20 mg
Total 350 mg

CA 02270952 1999-05-03
WO 98/22100 PCT/EP97/06408
-9-
Compounds of formula I in free form or in pharmaceutically acceptable salt
form are well
tolerated at dosages required for use in accordance with the present
invention. For
example, the acute LD5o is > 10 mg/kg p.o. in rats and monkeys.

Representative Drawing